6-K

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the financial year ended May 31, 2007

Lorus Therapeutics Inc.

(Translation of registrant’s name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7

(Address of principal executive offices)

[Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F.]

Form 20-F ___ X____             Form 40-F __  __     

[Indicate by check mark whether the registrant by

furnishing the information contained in this Form is also

thereby furnishing the information to the Commission pursuant

to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ________            No ____X___

[If "Yes" is marked, indicate below the file number

assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

EXHIBIT LIST

99.1        Voting Results

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of  1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lorus Therapeutics Inc.

Date: January 3, 2007

By:_ “Elizabeth Williams”_

Elizabeth Williams

Director of Finance

and Corporate Secretary

EX-99.1

Lorus Therapeutics Inc.

Report of Voting Results

(Section 11.3 of National Instrument 51-102)

In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, this report briefly describes the matter voted upon and the outcome of the votes at the Annual Shareholders’ Meeting of Lorus Therapeutics Inc. (the “Corporation”) held on September 21, 2006 in Toronto, Ontario.

1.  Appointment of Auditor:

KPMG LLP was appointed auditor of the Corporation until the Corporation’s next annual shareholders’ meeting and the Board of Directors was authorized to fix the auditor’s remuneration.

	Number	Percentage
FOR:	26,743,159	98.5
AGAINST:	0	0
WITHHELD FROM VOTING:	413,087	1.5
TOTAL:	27,156,246	100

2.  Election of Directors:

The following seven directors of the Corporation were elected for a term expiring not later than the Corporation’s next annual shareholders’ meeting:  J. Kevin Buchi, Donald W. Paterson, Georg Ludwig, Michael Moore, Alan Steigrod, Graham Strachan and Jim A. Wright.

	Number	Percentage
FOR:	26,105,908	96.1
AGAINST:	0	0
WITHHELD FROM VOTING:	1,050,338	3.9
TOTAL:	27,156,246	100

For additional information, please see the Company’s management information circular dated as of August 11, 2006 filed in connection with the Annual Shareholders’ Meeting.

Toronto, Ontario, October 2, 2006.

LORUS THERAPEUTICS INC.

“Elizabeth Williams”

Elizabeth Williams

Director of Finance and

Corporate Secretary